The English University of Oxford reported this Saturday that will resume clinical trials of the vaccine against Covid-19, after being recently discontinued after a volunteer in the UK suffered an adverse reaction.
In a statement, Oxford said that testing of the vaccine, dubbed ChAdOx1 nCoV-19, will resume in the UK after pause last day 6 as a precaution.
This possible vaccine, considered one of the most advanced developed in the world, is in the final phases of clinical trials before receiving authorization from regulatory agencies to proceed to immunize the population.
At the end of August, the EU closed a “first contract” with the British pharmaceutical company AstraZeneca that guaranteed the access to 300 million doses of the vaccine, so the suspension of the trials was a serious concern in Europe and around the world.
In its note to account for the resumption of testing, the university indicated that worldwide some 18,000 people have received this vaccine being studied as part of clinical trials and that, in tests as extensive as this, it is expected that some participants may feel bad.
“Each case must be carefully evaluated” to ensure the safety of the vaccine, added the Oxford statement, which has not specified the date of resumption of the trials.
Clinical trials in the UK they will start again upon completion of the independent review process.
“We cannot disclose medical information about (the volunteer’s) illness for reasons of participant confidentiality“explains the high house of study in his note.
“We are committed – he added – with the safety of our participants and the highest level of conduct in our studies and we will closely monitor the safety “of the vaccine.
The potential vaccine, which gave promising results in early trials, was undergoing clinical trials at the United Kingdom, United States, Brazil and South Africa.
Last month, the Governments of Argentina and Mexico, as well as the Mexican Slim Foundation, reached an agreement with AstraZeneca and the University of Oxford to manufacture the vaccine for their countries and then distribute it to the rest of Latin America, except Brazil.
The President of Argentina, Alberto Fernandez, reported in August that the goal was to produce between 150 and 250 million doses that would be available at affordable prices, at an individual cost of between $ 3-4.